ClinicalTrials.gov record
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa

ClinicalTrials.gov ID: NCT06603077

Public ClinicalTrials.gov record NCT06603077. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 8:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa (LOTUS)

Study identification

NCT ID
NCT06603077
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Avalo Therapeutics, Inc.
Industry
Enrollment
253 participants

Conditions and interventions

Interventions

  • AVTX-009 Regimen 1 Drug
  • AVTX-009 Regimen 2 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 15, 2024
Primary completion
Feb 22, 2026
Completion
Mar 16, 2026
Last update posted
Apr 20, 2026

2024 – 2026

United States locations

U.S. sites
36
U.S. states
17
U.S. cities
34
Facility City State ZIP Site status
Clinical Site 1022 Scottsdale Arizona 85260
Clinical Site 1037 Scottsdale Arizona 85260
Clinical Site 1026 Tucson Arizona 85704
Clinical Site 1032 Northridge California 91325
Clinical Site 1019 Pomona California 91767
Clinical Site 1009 Sacramento California 95815
Clinical Site 1034 Santa Monica California 90024
Clinical Site 1011 Washington D.C. District of Columbia 20010
Clinical Site 1029 Boca Raton Florida 33486
Clinical Site 1002 Coral Gables Florida 33134
Clinical Site 1015 Maitland Florida 32751
Clinical Site 1027 North Miami Beach Florida 33162-4708
Clinical Site 1013 Tampa Florida 33613
Clinical Site 1008 Savannah Georgia 31419
Clinical Site 1014 Chicago Illinois 60640
Clinical Site 1028 West Lafayette Indiana 47906
Clinical Site 1031 Bowling Green Kentucky 42104
Clinical Site 1024 Murray Kentucky 42071
Clinical Site 1042 Boston Massachusetts 02115-5804
Clinical Site 1001 Boston Massachusetts 02215
Clinical Site 1030 Detroit Michigan 48201
Clinical Site 1007 Fort Gratiot Michigan 48059
Clinical Site 1041 Oakland Michigan 48328
Clinical Site 1003 Portsmouth New Hampshire 03801
Clinical Site 1036 Brooklyn New York 10023
Clinical Site 1016 New York New York 10003
Clinical Site 1023 The Bronx New York 10467
Clinical Site 1020 Cincinnati Ohio 45219
Clinical Site 1010 Cleveland Ohio 44106
Clinical Site 1017 Dublin Ohio 43016
Clinical Site 1004 Philadelphia Pennsylvania 19103
Clinical Site 1035 Pittsburgh Pennsylvania 15213
Clinical Site 1018 Johnston Rhode Island 02919
Clinical Site 1025 Providence Rhode Island 02903
Clinical Site 1005 Greenville South Carolina 29615
Clinical Site 1012 Arlington Texas 76011

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06603077, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 20, 2026 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06603077 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →